Search

Displaying results 4311 - 4320 of 9670 in total
  1. Drug

    Mepiprazole

    go.drugbank.com/drugs/DB09197
    Experimental

    It acts as a 5-HT2A and α1-adrenergic receptor antagonist, and has also been shown to inhibit the reuptake and induce the release of serotonin, dopamine, and norepinephrine to varying extents. … It is a pyrazolyl-alkyl-piperazine derivative. Mepiprazole mediates a weak inhibitory action on the uptake of 5-HT on hypothalamic neurons [A7816].

  2. Drug

    Snail, unspecified

    go.drugbank.com/drugs/DB14245
    ApprovedInvestigational

    It is not an approved drug.

  3. Drug

    Purslane

    go.drugbank.com/drugs/DB14327
    Approved

    It is not an approved drug.

  4. Drug

    Methdilazine

    go.drugbank.com/drugs/DB00902
    Approved

    It is used in the treatment of various dermatoses to relieve pruritus.

  5. Drug

    Atipamezole

    go.drugbank.com/drugs/DB11481
    InvestigationalVet approved

    It has also been undergone research as a potential anti-Parkinsonian drug for humans.

  6. Drug

    DCFBC F-18

    go.drugbank.com/drugs/DB14772
    Investigational

    DCFBC F-18 is under investigation in clinical trial NCT02190279 (18F-DCFBC PET/CT in Prostate Cancer).

  7. Drug

    Guanoxan

    go.drugbank.com/drugs/DB13211
    Approved

    Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity.

  8. Drug

    Talactoferrin alfa

    go.drugbank.com/drugs/DB05426
    Investigational

    It increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation.

  9. Drug

    NUC B1000

    go.drugbank.com/drugs/DB05242
    Experimental

    On January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its experimental treatment for chronic Hepatitis B virus (HBV) infection.

  10. Drug

    Retifanlimab

    go.drugbank.com/drugs/DB15766
    ApprovedInvestigational

    By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells. … [L45603,L45613] The use of retifanlimab in combination with other oncology drugs for the treatment of metastatic gastroesophageal adenocarcinoma has also been evaluated.[A258383,A258388]